HIV pre-exposure prophylaxis for people who inject drugs: A review of current results and an agenda for future research

Journal of the International AIDS Society

Volumn 17, Issue , 2014, Pages

  Escudero, Daniel J ^a   Lurie, Mark N ^a   Kerr, Thomas ^b,c   Howe, Chanelle J ^a   Marshall, Brandon D L ^a  

^a BROWN UNIVERSITY   (United States)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HIV; Injection drug use; People who inject drugs; Pre exposure prophylaxis

Indexed keywords

TENOFOVIR;

DIRECTLY OBSERVED THERAPY; DRUG USE; EPIDEMIC; EVIDENCE BASED PRACTICE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; MISCELLANEOUS NAMED GROUPS; PATIENT ATTITUDE; PEOPLE WHO INJECT DRUG; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS TRANSMISSION;

HIV; INJECTION DRUG USE; PEOPLE WHO INJECT DRUGS; PRE-EXPOSURE PROPHYLAXIS;

ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; BIOMEDICAL RESEARCH; FORECASTING; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84899925339     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.1.18899     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention. HIV surveillance report, 2011 [Internet]. 2013 [cited 2013 May]; vol. 23. Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/
2. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7(2):99-106.
3. Donoghoe MC, Verster, AD, Mathers B. Technical guide: for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: WHO, UNODC, UNAIDS; 2012. ISBN 978 92 4 150437 9.
4. UNAIDS. HIV prevention among injecting drug users. 24th meeting of the UNAIDS Programme Coordinating Board; Geneva, Switzerland: UNAIDS; 2009.
5. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel: an antiretroviral microbicide for the prevention of HIV infection in women. Science. 2010; 329:1168.
7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
8. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883): 2083-90.
9. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS. 2011;25:383.
10. Vaginal and Oral Interventions to Control the Epidemic (VOICE). MTN statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women [Internet]. 2011 [cited 2011 Sep 28]; Microbicide Trials Network. Available from: http://www.mtnstopshiv.org/node/3619
11. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010; 375(9719):1014-28.
12. Sarin E, Samson L, Sweat M, Beyrer C. Human rights abuses and suicidal ideation among male injecting drug users in Delhi, India. Int J Drug Policy. 2011;22(2):161-6.
13. Fairbairn N, Kaplan K, Hayashi K, Suwannawong P, Lai C, Wood E, et al. Reports of evidence planting by police among a community-based sample of injection drug users in Bangkok, Thailand. BMC Int Health Hum Rights. 2009;9:24.
14. Strathdee SA, Shoptaw S, Dyer TP, Quan VM, Aramrattana A. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention. Curr Opin HIV AIDS. 2012;7(4):320-5.
15. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9.
16. Smith DK, Dearing JW, Sanchez T, Goldschmidt RH. Introducing wicked issues for HIV pre-exposure prophylaxis implementation in the U.S. Am J Prev Med. 2013;44(1 Suppl 2):S59-62.
17. Baral SD, Stromdahl S, Beyrer C. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Curr Opin HIV AIDS. 2012;7(6):563-8.
18. Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr. 2010; (55 Suppl 2):S84-7.
19. Flash C, Krakower D, Mayer KH. The promise of antiretrovirals for HIV prevention. Curr Infect Dis Rep. 2012;14(2):185-93.
20. Dutta MJ. Disseminating HIV pre-exposure prophylaxis information in underserved communities. Am J Prev Med. 2013;44(1 Suppl 2):S133-6.
21. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012; 7(1):e28238.
22. Choopanya K, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R, Leethochawalit M, et al. Enrollment, follow-up, and risk behavior of injecting drug users in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Bangkok, Thailand [TUPE358]. Presented at 6th IAS Conference on HIV Pathogenesis and Treatment; Rome; 2011 Jul 17-20.
23. Choopanya K, Vanichseni S, Suntharasamai P, Sangkum U, Leethochawalit M, Chiamwongpaet S, et al. HIV associated risk behaviour among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok, Thailand [WEPE266]. Presented at 19th International AIDS Conference; Washington, DC; 2012 Jul 22-27.
24. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R, Mock PA, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One. 2011;6(9):e25127.
25. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Leethochawalit M, Chiamwongpaet S, et al. Participant adherence in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Bangkok [WEPE272]. Presented at 19th International AIDS Conference; Washington, DC; 2012 Jul 22-27.
26. Vanichseni S, Martin M, Suntharasamai P, Sangkum U, Leethochawalit M, Chiamwongpaet S, et al. Morbidity and mortality of injecting drug users participating in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Thailand [WEPE267]. Presented at 19th International AIDS Conference; Washington, DC; 2012 Jul 22-27.
27. Vanichseni S, Martin M, Suntharasamai P, Sangkum U, van Griensven F, Mock P, et al. Trends and predictors of HIV-associated risk behaviors among injecting drug users participating in an HIV prevention trial, Bangkok [MOAC201]. Presented at 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Sydney; 2007 Jul 22-25.
28. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic [Internet]. 2012 [cited 2013 May 15]. Available from: http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/2012/gr2012/ 20121120-UNAIDS-Global-Report-2012-en.pdf
29. Campbell JD, Herbst JH, Koppenhaver RT, Smith DK. Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med. 2013;44(1 Suppl 2):S63-9.
30. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2012;26(2):87-94.
31. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248-54.
32. Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall JM, Cook E, et al. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care. 2012;24(4):468-77.
33. Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One. 2012;7(3):e32329.
34. Poynten IM, Jin F, Prestage GP, Kaldor JM, Imrie J, Grulich AE. Attitudes towards new HIV biomedical prevention technologies among a cohort of HIV-negative gay men in Sydney, Australia. HIV Med. 2010;11(4):282-8.
35. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011; 8(11):e1001123.
36. Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One. 2008;3(5):e2077.
37. Pretorius C, Stover J, Bollinger L, Bacaer N, Williams B. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One. 2010;5(11):e13646.
38. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E,Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806-15.
39. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis. 2012;54(10):1504-13.
40. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1 serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62(3):339-47.
41. Matthews LT, Smit JA, Cu-Uvin S, Cohan D. Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS. 2012;7(6):569-78.
42. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25(2):63-71.
43. Poynten IM, Zablotska I, Grulich AE. Considerations regarding antiretroviral chemoprophylaxis in MSM. Curr Opin HIV AIDS. 2012;7(6):549-56.
44. Centers for Disease Control and Prevention (CDC). Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep, 2013; 62(23):463-5.
45. Curran JW, Crosby RA. Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges? Am J Prev Med. 2013;44(1 Suppl 2):S163-6.
46. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731-47.
47. Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for "treatment as prevention." Curr Opin HIV AIDS. 2012;7(4):332-8.
48. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011; 113(2-3):192-9.
49. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;(56 Suppl 1):S22-32.
50. Abdul-Quader AS, Feelemyer J, Modi S, Stein ES, Briceno A, Semaan S, et al. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878-92.
51. Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(4 Suppl 3):iii7-14.
52. Wolfe D. Beyond the hype: PrEP for people who inject drugs. The Huffington Post [Internet]. 2013 [cited 2013 Jul 22]. Available from: http:// www.huffingtonpost.com/daniel-wolfe/beyond-the-hype-prep-for--b-3437910.html